COVID-19 and Lingering Symptoms in Primary Care Patients

Completed

• Conditions: Covid19; Symptoms and Signs

• Registration Number: NCT04813731
• Lead Sponsor: Katarina Hedin

Brief Summary

The ongoing corona virus disease 2019 (COVID-19) is a viral acute respiratory tract infection caused by server acute respiratory syndrom coronavirus typ 2 (SARS-CoV-2). The signs and symptom of SARS-CoV-2 infection vary and most people with COVID-19 experience illness of mild or moderate severity and recover with symptomatic treatment outside of hospital. Studies have found that some people experience lingering/long-lasting symptoms and only a minority of patients were completely free from COVID-19 related symptoms after two months. About one third still had up to two residual symptoms and 55% had three or more. As far as we know no study on lingering symptoms has been published in patients after a mild or moderate infection managed in primary care settings. The aim of this study is to explore the course of disease over a one year period and describe lingering symptoms and their impact on well-being and daily activities in adult non-hospitalized patients with previous established COVID-19 infection.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-12-12
• Study First Submitted: 2021-03-07
• Study First Submitted QC: 2021-03-23
• Study First Posted: 2021-03-24
• Primary Completion: 2022-06-30
• Study Completion: 2022-06-30
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-01
• Last Update Posted: 2024-12-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Confirmed SARS-CoV-2 infection, either by polymeras chain reaction (PCR), or by antigen testing (if authorized/recommended/used by national/local governments)
• Symptoms consistent with mild to moderate COVID-19
• Maximum of 2 weeks since positive SARS-CoV-2 test
• Aged 18 years and older
• Patient able and willing to comply with monthly phone calls.

Exclusion Criteria

• Hospitalisation due to COVID-19

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time to full recovery symptoms	through study completion, a maximum of 1 year	Number of weeks until "back to normal"

Trial Locations

Locations (13)

Centre for General Practice, Department of Family Medicine & Population Health (FAMPOP), Faculty of Medicine and Health Sciences, University of Antwerp; 🇧🇪 Antwerp, Belgium

the Academic Centre for General Practice (ACHG), Department of Public Health and Primary Care, KU Leuven; 🇧🇪 Leuven, Belgium

Center for General Practice at Aalborg University; 🇩🇰 Aalborg, Denmark

Département de Santé Publique, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France; 🇫🇷 Nice, France

R. Lugar Center for Public Health Research; 🇬🇪 Tbilisi, Georgia

Institut für Allgemeinmedizin Universitätsklinikum Würzburg Josef-Schneider-Str. 2/D7 97080 Würzburg; 🇩🇪 Würzburg, Germany

School of Medicine, National University of Ireland; 🇮🇪 Galway, Ireland

Covid-19 primary care special unit Sassuolo, Azienda Unità Sanitaria locale di Modena, Modena, Italy; 🇮🇹 Modena, Italy

Julius Center, University Medical Center Utrecht; 🇳🇱 Utrecht, Netherlands

Medical University of Lodz, Lodz; 🇵🇱 Łódź, Poland

Balan Medfam SRL; 🇷🇴 Cluj Napoca, Romania

Wetterhälsan Primary Health Care Centre; 🇸🇪 Jönköping, Sweden

Kärna Primary Health Care Centre; 🇸🇪 Linköping, Sweden